SCHEMBL250251

SCHEMBL250251

Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)C[C@H]1O

nearest known ligand 0.75

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ P2RX1 P51575 4/20 0.70
▸ P2RX3 P56373 4/20 0.70
▸ P2RX2 Q9UBL9 2/20 0.70
▸ P2RY1 P47900 6/20 0.67
▸ P2RX4 Q99571 3/20 0.67
▸ P2RY2 P41231 2/20 0.67
▸ SRC P12931 1/20 0.67
▸ ALDH1A1 P00352 1/20 0.67
▸ SMN1; SMN2 Q16637 1/20 0.67
▸ RNASEL Q05823 1/20 0.65
▸ MACROD2 A1Z1Q3 1/20 0.63
▸ SIRT6 Q8N6T7 1/20 0.63
▸ MACROD1 Q9BQ69 1/20 0.63
▸ TRPM2 O94759 1/20 0.63
▸ PARG Q86W56 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20419143 1.00 P2RX1 (0.70) P2RX1P2RX3P2RX2P2RY1P2RX4
SCHEMBL29476737 1.00 P2RX1 (0.70) P2RX1P2RX3P2RX2P2RY1P2RX4
SCHEMBL19493160 1.00 P2RX1 (0.70) P2RX1P2RX3P2RX2P2RY1P2RX4
SCHEMBL29476738 1.00 P2RX1 (0.70) P2RX1P2RX3P2RX2P2RY1P2RX4
SCHEMBL250252 1.00 P2RX1 (0.70) P2RX1P2RX3P2RX2P2RY1P2RX4
SCHEMBL3163036 1.00 P2RX1 (0.70) P2RX1P2RX3P2RX2P2RY1P2RX4
SCHEMBL23982340 1.00 P2RX1 (0.70) P2RX1P2RX3P2RX2P2RY1P2RX4
SCHEMBL12932304 1.00 P2RX1 (0.70) P2RX1P2RX3P2RX2P2RY1P2RX4
SCHEMBL23856115 0.99 P2RX1 (0.69) P2RX1P2RX3P2RX2P2RY1P2RX4
SCHEMBL22498804 0.99 P2RX1 (0.68) P2RX1P2RX3P2RX2P2RY1P2RX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 352 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240390479-A1 TAIL-CONJUGATED RNAS TIBA BIOTECH (US) 2024-11-28 — — US claimed
WO-2023212213-A1 TAIL-CONJUGATED RNAS TIBA BIOTECH (US) 2023-11-02 — — WO claimed
EP-4150065-A2 GENERATING NUCLEIC ACIDS WITH MODIFIED BASES USING RECOMBINANT TERMINAL DEOXYNUCLEOTIDYL TRANSFERASE Illumina Inc (US) 2023-03-22 — — EP claimed
US-20220305128-A1 COMPOSITIONS COMPRISING CIRCULAR POLYRIBONUCLEOTIDES FOR PROTEIN MODULATION AND USES THEREOF FLAGSHIP PIONEERING INNOVATIONS VI, LLC 2022-09-29 — — US claimed
EP-3986469-A1 COMPOSITIONS COMPRISING CIRCULAR POLYRIBONUCLEOTIDES FOR PROTEIN MODULATION AND USES THEREOF Flagship Pioneering Innovations VI, LLC (US) 2022-04-27 — — EP claimed
US-10144972-B2 Composition for hot-start reverse transcription reaction or hot-start reverse transcription polymerase chain reaction BIONEER CORPORATION (KR) 2018-12-04 — — US claimed
EP-2824189-B1 COMPOSITION FOR HOT-START REVERSE TRANSCRIPTION REACTION OR HOT-START REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION BIONEER CORP (KR) 2018-01-31 — — EP claimed
EP-2837696-B1 HIGH-SENSITIVITY NUCLEIC ACID PREPARATION METHODS FOR THE DETECTION OF NUCLEIC ACID BY NUCLEIC ACID POLYMERASE BIONEER CORP (KR) 2018-01-31 — — EP claimed
US-20150072351-A1 HIGH-SENSITIVITY NUCLEIC ACID PREPARATION METHODS FOR THE DETECTION OF NUCLEIC ACID BY NUCLEIC ACID POLYMERASE BIONEER CORPORATION (KR) 2015-03-12 — — US claimed
EP-2837696-A2 METHOD FOR PREPARING A NUCLEIC ACID WITH HIGH PRECISION USED IN DETECTING A NUCLEIC ACID WITH A NUCLEIC ACID POLYMERASE Bioneer Corporation (KR) 2015-02-18 — — EP claimed
US-20150044683-A1 COMPOSITION FOR HOT-START REVERSE TRANSCRIPTION REACTION OR HOT-START REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION BIONEER CORPORATION (KR) 2015-02-12 — — US claimed
EP-2824189-A1 COMPOSITION FOR HOT-START REVERSE TRANSCRIPTION REACTION OR HOT-START REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION Bioneer Corporation (KR) 2015-01-14 — — EP claimed
EP-2451980-B1 CHEMICALLY MODIFIED LIGASE COFACTORS, DONORS AND ACCEPTORS TRILINK BIOTECHNOLOGIES (US) 2014-05-21 — — EP claimed
US-8728725-B2 Chemically modified ligase cofactors, donors and acceptors TRILINK BIOTECHNOLOGIES (US) 2014-05-20 — — US claimed
US-20110008788-A1 CHEMICALLY MODIFIED LIGASE COFACTORS, DONORS AND ACCEPTORS TriLink Bio Technologies 2011-01-13 — — US claimed
US-20060057583-A1 Novel compositions and methods for controlling the extendability of various components used in copying or amplification steps ENZO LIFE SCIENCES, INC. C/O ENZO BIOCHEM, INC. 2006-03-16 — — US claimed
US-4708935-A (2-5')-Oligo (3'-deoxyadenylate) and derivatives thereof RESEARCH CORPORATION (US) 1987-11-24 — — US claimed
US-12636369-B2 Compositions comprising circular polyribonucleotides for protein modulation and uses thereof FLAGSHIP PIONEERING INNOVATIONS VI, LLC (US) 2026-05-26 — — US disclosed
US-4464359-A VIRICIDES RESEARCH CORPORATION (US) 1984-08-07 — — US disclosed
US-4464359-A VIRICIDES RESEARCH CORPORATION (US) 1984-08-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220305128-A1 COMPOSITIONS COMPRISING CIRCULAR POLYRIBONUCLEOTIDES FOR PROTEIN MODULATION AND USES THEREOF RNMT, NSUN3, NSUN2 P2RX1 4186/4885P2RX3 3941/4885P2RX2 4029/4885
US-12636369-B2 Compositions comprising circular polyribonucleotides for protein modulation and uses thereof USP25, RBM25, TRIM25 P2RX1 3483/4885P2RX3 3793/4885P2RX2 3106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback